Top Markets
Coin of the day
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
株式のランク #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
株価
$0.07339369
最終同期: 2026-08-18
時価総額
$25.24M
変化(1日)
5.26%
変化(1年)
-9.55%
CA
取引 Resverlogix Corp. (RVX)

カテゴリー

Resverlogix Corp.(RVX)の株価履歴
終値の最高値: $0.07 (2026-08-01)

終値の最安値: $1.62 (2004-05-01)
Resverlogix Corp. の株価履歴(2004 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -6.81%
2025 102.06%
2024 -21.85%
2023 -56.62%
2022 -70.32%
2021 -46.30%
2020 -22.98%
2019 -58.94%
2018 55.79%
2017 15.32%
2016 3.07%
2015 197.15%
2014 -11.34%
2013 -71.83%
2012 26.66%
2011 -46.99%
2010 4.14%
2009 49.40%
2008 -88.69%
2007 34.88%
2006 78.65%
2005 76.80%
2004 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$552.07 41.28%
US
$168.77 504.69%
US
$1.03K 57.19%
NL
$117.42 -19.34%
AU
$753.28 8.59%
CH